Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Cash from Financing Activities: 2021-2025

Historic Cash from Financing Activities for Roivant Sciences (ROIV) over the last 5 years, with Mar 2025 value amounting to -$1.2 billion.

  • Roivant Sciences' Cash from Financing Activities rose 157.38% to $62.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 1062.61%. This contributed to the annual value of -$1.2 billion for FY2025, which is 390.87% down from last year.
  • Roivant Sciences' Cash from Financing Activities amounted to -$1.2 billion in FY2025, which was down 390.87% from $419.4 million recorded in FY2024.
  • Roivant Sciences' Cash from Financing Activities' 5-year high stood at $499.5 million during FY2023, with a 5-year trough of -$1.2 billion in FY2025.
  • Moreover, its 3-year median value for Cash from Financing Activities was $419.4 million (2024), whereas its average is -$100.3 million.
  • As far as peak fluctuations go, Roivant Sciences' Cash from Financing Activities skyrocketed by 62.80% in 2023, and later tumbled by 390.87% in 2025.
  • Yearly analysis of 5 years shows Roivant Sciences' Cash from Financing Activities stood at $456.3 million in 2021, then slumped by 32.76% to $306.8 million in 2022, then surged by 62.80% to $499.5 million in 2023, then dropped by 16.04% to $419.4 million in 2024, then slumped by 390.87% to -$1.2 billion in 2025.